Seres Therapeutics, Inc. develops live biotherapeutic products and microbiome-based therapies for inflammatory, immune, infectious and gastrointestinal diseases. Company updates commonly address pipeline programs such as SER-155 for immune checkpoint inhibitor-related enterocolitis and prevention of bloodstream infections in allogeneic hematopoietic stem cell transplant patients, SER-603 for inflammatory bowel disease, and SER-428 for antimicrobial resistance and serious infections.
Recurring announcements include financial results, operational updates, research publications, scientific conference presentations, biomarker and microbiome-mechanism data, collaborations, financing and partnership activity, cost-control measures, and governance changes.
Seres Therapeutics (MCRB) reported inducement equity grants made on September 4, 2026 under its 2022 Employment Inducement Award Plan to two new employees.
The Compensation and Talent Committee granted stock options to purchase an aggregate of 4,200 shares of Seres common stock, with an exercise price of $5.72 per share. The Inducement Plan is used exclusively for equity awards that serve as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4) and was adopted by the board in December 2022. Each option vests 25% on the first anniversary of the individual’s hire date, with the remaining 75% vesting in 6.25% increments after each three full months of continued service thereafter.
Seres Therapeutics (Nasdaq: MCRB) announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY. The company will present a corporate overview at 2:00 p.m. ET on September 15, 2026, with a live webcast and replay available via the Events and Presentations section of its website.
Seres Therapeutics (Nasdaq:MCRB) reported second quarter 2026 net income of $4.6 million, versus a $19.9 million loss a year earlier, mainly driven by a $25 million gain on sale of the VOWST business tied to a milestone termination payment from Nestlé Health Science.
R&D expenses fell to $9.1 million and G&A to $7.1 million, partly offset by a $5.8 million lease impairment. Seres announced early termination of its 200 Sidney Street lease and a previously restructured 101 CambridgePark Drive lease, which are expected to materially reduce future facility cash costs and lease obligations.
Clinically, an MSK investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis showed 80% of 15 participants achieved immunosuppressive-free clinical response at day 15, with no safety concerns identified. Cash and equivalents were $15.6 million on June 30, 2026, and the company expects its cash, including Nestlé payments, to fund operations into the first quarter of 2027.
Seres Therapeutics (Nasdaq:MCRB) reported early clinical data from a 15-patient MSK investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC).
At Day 15, 80% achieved immunosuppressive-free clinical response and 33% complete remission; SER-155 was generally well tolerated and showed biomarker and microbiome engraftment changes supporting further development.
Seres Therapeutics (Nasdaq:MCRB) will host a webcast on July 8, 2026, at 8:30 a.m. ET to discuss top-line results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis.
The event will be accessible via conference call and live webcast with replay available.
Seres Therapeutics (Nasdaq:MCRB) announced two transactions to bolster liquidity and cut facility costs. Nestlé Health Science will pay $25 million in 2026 to buy out future VOWST net sales milestones, and a restructured lease is expected to materially lower annual facility cash spending and long-term obligations.
With $29.8 million in cash as of March 31, 2026, Seres now expects its operating cash runway to extend well into Q1 2027 and anticipates SER-155 clinical data in immune checkpoint inhibitor-related enterocolitis later this month.
Seres Therapeutics (Nasdaq:MCRB) announced that management will present a company overview at the H.C. Wainwright 4th Annual BioConnect Investor Conference at 3:30 p.m. ET on May 19, 2026.
A live webcast and replay will be available via the company’s investor relations website.
Seres (Nasdaq: MCRB) reported Q1 2026 results and business updates on May 5, 2026. Key items: investigator-sponsored SER-155 irEC study readout expected in the coming weeks (15 patients enrolled), SER-155 Phase 2 readiness for allo-HSCT, IND-enabling work for SER-603, CARB-X–supported SER-428 development, and $29.8M cash expected to fund operations through Q3 2026.
Q1 2026 net loss was $19.9M versus net income of $32.7M in Q1 2025; R&D was $13.2M and G&A was $8.1M.
Seres Therapeutics (Nasdaq: MCRB) presented preclinical data at Digestive Disease Week 2026 supporting SER-603, a next-generation cultivated live biotherapeutic candidate for inflammatory bowel disease (IBD). The poster was selected as a DDW Poster of Distinction and highlights rational strain selection, biomarker-driven patient stratification, and IND-enabling progress.
Data show SER-603 reduced inflammatory cytokine production in a MiGUT in vitro gut model and the company reports engagement with potential collaborators to support clinical development.
Seres Therapeutics (Nasdaq: MCRB) presented Phase 1b and translational data at ESCMID Global 2026 (April 17–21). Seres reported that SER-155 induced a significant, durable shift in GI microbiome composition and was associated with improved GI epithelial barrier integrity versus placebo.
Presentations included a SER-155 poster, an oral MiGut model talk with University of Leeds collaboration, and a symposium on microbiome strategies in immunocompromised patients.